TY - JOUR
T1 - Blockade of NF-κB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II
AU - Kawano, Shunichi
AU - Kubota, Toru
AU - Monden, Yoshiya
AU - Kawamura, Natsumi
AU - Tsutsui, Hiroyuki
AU - Takeshita, Akira
AU - Sunagawa, Kenji
N1 - Funding Information:
A part of this study was conducted in Kyushu University Station for Collaborative Research. This study was supported by a grant from Kimura Memorial Heart Foundation, by the Grant for Research on Cardiovascular Disease from Japan Heart Foundation/Pfizer Pharmaceuticals Inc., and by the Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (C15590755).
PY - 2005/9/1
Y1 - 2005/9/1
N2 - Objective: Nuclear factor (NF)-κB is a key transcription factor that regulates inflammatory processes. In the present study, we assessed the hypothesis that blockade of NF-κB may ameliorate ventricular hypertrophy in response to chronic infusion of angiotensin II. Methods: Mice with targeted disruption of the p50 subunit of NF-κB (KO) were used to block the activation of NF-κB. Male KO and age-matched wild-type (WT) mice were chronically infused with angiotensin II at the rate of 0.2 (low dose) or 2 μg/kg/min (high dose) for 4 weeks. Results: High- but not low-dose angiotensin II significantly increased systemic blood pressure and left ventricular weight in WT mice. In contrast, although the pressor response was slightly but significantly augmented, the hypertrophic effect of angiotensin II was significantly attenuated in KO mice. The attenuated hypertrophic responsiveness was confirmed histologically (cross-sectional area) and transcriptionally (atrial natriuretic peptide). Echocardiography revealed no evidence of cardiac dysfunction in angiotensin II-treated KO mice. Although phosphorylation of MAPKs, including ERK, JNK, or p38-MAPK, was not affected after 4 weeks of angiotensin II treatment in WT mice, phosphorylation of JNK was specifically abrogated in KO mice. Angiotensin II increased myocardial expression of proinflammatory cytokines and chemokines in WT mice, while expression of TNF-α and RANTES was paradoxically augmented in KO mice. Conclusion: Blockade of NF-κB activation attenuated myocardial hypertrophy without deteriorating cardiac function. NF-κB may play an important role in cardiac hypertrophy and remodeling besides promoting inflammation.
AB - Objective: Nuclear factor (NF)-κB is a key transcription factor that regulates inflammatory processes. In the present study, we assessed the hypothesis that blockade of NF-κB may ameliorate ventricular hypertrophy in response to chronic infusion of angiotensin II. Methods: Mice with targeted disruption of the p50 subunit of NF-κB (KO) were used to block the activation of NF-κB. Male KO and age-matched wild-type (WT) mice were chronically infused with angiotensin II at the rate of 0.2 (low dose) or 2 μg/kg/min (high dose) for 4 weeks. Results: High- but not low-dose angiotensin II significantly increased systemic blood pressure and left ventricular weight in WT mice. In contrast, although the pressor response was slightly but significantly augmented, the hypertrophic effect of angiotensin II was significantly attenuated in KO mice. The attenuated hypertrophic responsiveness was confirmed histologically (cross-sectional area) and transcriptionally (atrial natriuretic peptide). Echocardiography revealed no evidence of cardiac dysfunction in angiotensin II-treated KO mice. Although phosphorylation of MAPKs, including ERK, JNK, or p38-MAPK, was not affected after 4 weeks of angiotensin II treatment in WT mice, phosphorylation of JNK was specifically abrogated in KO mice. Angiotensin II increased myocardial expression of proinflammatory cytokines and chemokines in WT mice, while expression of TNF-α and RANTES was paradoxically augmented in KO mice. Conclusion: Blockade of NF-κB activation attenuated myocardial hypertrophy without deteriorating cardiac function. NF-κB may play an important role in cardiac hypertrophy and remodeling besides promoting inflammation.
UR - http://www.scopus.com/inward/record.url?scp=22744444997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22744444997&partnerID=8YFLogxK
U2 - 10.1016/j.cardiores.2005.04.030
DO - 10.1016/j.cardiores.2005.04.030
M3 - Article
C2 - 15921667
AN - SCOPUS:22744444997
SN - 0008-6363
VL - 67
SP - 689
EP - 698
JO - Cardiovascular research
JF - Cardiovascular research
IS - 4
ER -